Rationale: Lamina-associated polypeptide (LAP)2␣ is a mammalian chromatin-binding protein that interacts with a fraction of A-type lamins in the nuclear interior. Because mutations in lamins and LAP2␣ lead to cardiac disorders in humans, we hypothesized that these factors may play important roles in heart development and adult tissue homeostasis. Objective: We asked whether the presence of LAP2␣ was required for normal cardiac function. Methods and Results: To study the molecular mechanisms of the disease, we analyzed heart structure and function in complete and conditional Lap2␣ ؊/؊ mice as well as Lap2␣ ؊/؊ /Mdx mutants. Unlike conditional deletion of LAP2␣ in late embryonic striated muscle, its complete knockout caused systolic dysfunction in young mice, accompanied by sporadic fibrosis in old animals, as well as deregulation of major cardiac transcription factors GATA4 and myocyte enhancer factor 2c. Activation of compensatory pathways, including downregulation of ␤-adrenergic receptor signaling, resulted in reduced responsiveness of the myocardium to chronic ␤-adrenergic stimulation and stalled the progression of LAP2␣-deficient hearts from hypertrophy toward cardiac failure. 
D
ilated cardiomyopathy (DCM) is a primary myocardial disease characterized by dilation and impaired contraction of one or both heart ventricles. One of the genes most frequently involved in the development of DCM is LMNA, which encodes the nuclear intermediate filament proteins lamin A and lamin C 1 . Mutations in lamin A/C cause the most severe forms of DCM, posing a high risk of heart failure in symptomatic patients. 1 Besides heart muscle disease, mutations in LMNA cause a variety of pathological conditions in skeletal muscle, skin, nerve, bone, and adipose tissue, known as laminopathies, 2 emphasizing the importance of the search for molecular disease mechanisms.
Recently, research on laminopathies has focused on lamin A/C-interacting proteins, whose mutations have been linked to a similar spectrum of human disorders. 3 One of the best studied lamin A/C-binding partners is lamina associated polypeptide (LAP)2␣, an unusual splice variant of the mammalian LAP2 gene. 4 All LAP2 proteins (␣, ␤, ␥, ␦, , ) share a common chromatin-binding structural motif called the LEM (LAP2-emerin-MAN1) domain at their N terminus. The C terminus of most LAP2 variants comprises a transmembrane region, which targets them to the inner nuclear membrane, where they serve mainly structural roles. 5 LAP2␣ lacks the common LAP2 transmembrane domain and possesses an additional chromatin-binding region at its C-terminal end, which mediates targeting to the nuclear interior. 4 In the nucleoplasm LAP2␣ specifically interacts with a fraction of lamin A/C via its unique C-terminal tail. 6 Together, LAP2␣ and lamin A/C influence various nuclear processes, such as epigenetic chromatin regulation, gene expression, and signal transduction. 7 In particular, LAP2␣-lamin A/C complexes have been found to control the balance between proliferation and differentiation of early progenitor cells in regenerative tissues by affecting the E2F/retinoblastoma pathway. 8 Interestingly, a mutation in LAP2␣ (c. 2068CϾT, p. R690C), which lowers its binding affinity for lamin A/C in vitro, has also been linked to DCM. 9 Because changes in both LAP2␣ and lamin A/C cause pathological heart conditions, we hypothesized that an intact LAP2␣-lamin A/C complex may be necessary for proper cardiac function and that mislocalization or absence of one of the components would lead to disease.
Most Lmna transgenic mice generated so far show complex phenotypes, including various stages of heart failure. 10, 11 To see whether the presence of LAP2␣ is also important for normal cardiac output, we analyzed heart structure and function in previously generated Lap2␣ Ϫ/Ϫ mice. 8 Here, we describe a new mouse model of cardiomyopathy and provide novel insights into mechanisms governing heart development and tissue homeostasis.
Methods

Mice
Lap2␣
Ϫ/Ϫ mice were kept on a mixed Mus musculus C57BL/6ϫ129 genetic background. 8 Compound mutant Lap2␣ Ϫ/Ϫ /Mdx animals were obtained by crossing Lap2␣ Ϫ/Ϫ mice with the Mdx line. 12 Generation of conditional LAP2␣ knockout (KO) mice is described in Online Figure I (available in the Online Data Supplement at http://circres.ahajournals.org). All histological and physiological analyses were done by observers blinded for the genotype, as well as treatment of the animal. Mice aged 2 days were considered as newborn, 10 weeks as young, and 10 to 12 months as old.
Mice were kept and handled in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals. Experiments were performed according to permissions from Austrian authorities.
Echocardiography
Mice were anesthetized with 5% isoflurane/O 2 and maintained on 2% mixture during the experiment. Transthoracic echocardiography was performed using Vingmed Vivid Five (GE Technology) equipped with a 10-MHz linear transducer. 13 Gravimetric, histological, and biochemical analyses were performed according to standard procedures described in more detail in the Online Data Supplement.
Isoproterenol-Induced Heart Failure Model
Mice anesthesia and echocardiography were performed as described above. Alzet miniosmotic pumps (1007D), filled with 15 mg/kg per day isoproterenol (ISO)/PBS, were implanted according to the instructions of the manufacturer (DURECT Corp.). Six old male Lap2␣ ϩ/ϩ and 7 Lap2␣ Ϫ/Ϫ mice were infused with ISO for 7 days and 2 littermate couples received only PBS (sham).
Statistical Analysis
Experimental outliers were identified using Grubb's test and excluded from further analyses. 
Results
LAP2␣-deficient mice used in this study were generated by Cre recombinase-mediated excision of the LAP2␣-specific exon 4 of the Lap2 gene in the germline. 8 To confirm the absence of the gene product, we performed Western blot, semiquantitative PCR, and immunofluorescence analyses of Lap2␣ Ϫ/Ϫ heart muscle tissue. LAP2␣ was detectable neither at an mRNA nor a protein level, whereas the expression, as well as localization, of lamin A/C and other LAP2 isoforms were not significantly altered ( Figure 1 and Online Figure II) .
Absence of LAP2␣ Causes Ventricular Systolic Dysfunction in Mice
The symptoms in LAP2␣-and most lamin A/C-linked human cardiomyopathies appear predominantly in adults. 5, 9 In mouse lamin A/C-linked laminopathy models, however, heart defects develop in young animals and cause early mortality. 10, 11 As Lap2␣ Ϫ/Ϫ mice are grossly indistinguishable from their WT littermates and have a normal life expectancy, 8 we analyzed heart function in young, as well as old animals. Echocardiography in 10-week-old Lap2␣ (Figure 2 and Online Table I ). The FS% and percentage ejection fraction values remained similarly depressed in old Lap2␣ Ϫ/Ϫ male mice (aged 10 to 12 months), suggesting that the functional defect was not progressive. Interestingly, cardiac parameters in Lap2␣ Ϫ/Ϫ females appeared largely comparable to WT at both ages (Online Table I ).
Old Lap2␣ ؊/؊ Mice Present Only Sporadic Cases of Cardiac Fibrosis
To see whether the functional defect in Lap2␣ Ϫ/Ϫ hearts was accompanied by structural changes, we performed gravimetric and histological analyses. Lap2␣ Ϫ/Ϫ hearts had normal morphology and similar heart weight/body weight indexes compared to WT littermates in newborn, young, and old animals (data not shown). Furthermore, no overt histological pathologies were detectable in young Lap2␣ Ϫ/Ϫ mice ( Figure  3A ). Old Lap2␣ Ϫ/Ϫ hearts, however, showed high phenotypic variability in the degree of fibrosis, as assessed by the extent of interstitial collagen deposition in the left ventricle. Although the overall difference in the extent of cardiac fibrosis between Lap2␣ Ϫ/Ϫ and WT mice was found to be statistically insignificant (Online Figure III) , of 11 Lap2␣ Ϫ/Ϫ tested mice, 18% developed extensive subendocardial fibrosis of the left ventricle ( Figure 3B ). In addition to fibrosis, 1 mouse presented regions of extremely thin, transparent myocardium, which collapsed in the absence of internal blood pressure ( Figure 3C ). In contrast, WT animals did not exhibit signs of increased fibrosis at any age.
Deregulated Expression of Major Cardiac Transcription Factors in Male LAP2␣-Deficient Mice
In an attempt to identify the molecular mechanisms leading to systolic dysfunction in Lap2␣
Ϫ/Ϫ mice, we analyzed the expression of several markers connected to myocardial remodeling. Two major cardiac transcription factors, GATA4 and MEF2c, as well as their downstream targets (brain natriuretic peptide [BNP] and proteins involved in serum response factor-mediated transcription of immediate early and muscle-specific genes, myocardin A and STARS [striated muscle activator of Rho signaling] 14 -18 ), showed deregulated expression patterns in male Lap2␣ Ϫ/Ϫ mice ( Figure 4A and 4B). Whereas MEF2c expression was repressed in newborn Lap2␣ Ϫ/Ϫ hearts and reached WT levels by the age of 10 weeks, GATA4, myocardin A and STARS were downregulated only in old hearts. In addition, consistent with the reported cooperative regulation of BNP expression by both GATA4 and MEF2c, 18 BNP mRNA levels were significantly lower in LAP2␣-deficient hearts compared to WT at all ages ( Figure 4A ). The expression of other MEF2c and GATA4 targets, such as ␣-and ␤-myosin heavy chain and atrial natriuretic factor 19 was not significantly changed in Lap2␣ Ϫ/Ϫ mice (data not shown). The expression of the aforementioned factors in female Lap2␣ Ϫ/Ϫ hearts was comparable to WT (data not shown). Our data show that loss of LAP2␣ affects the expression of GATA4 and MEF2c, as well as some of their downstream targets, which in turn may influence the expression of a plethora of genes involved in cardiovascular development and stress-induced hypertrophic growth.
Because old Lap2␣ Ϫ/Ϫ mice showed occasional fibrosis, we analyzed the expression of known fibrotic markers in WT and LAP2␣-deficient hearts ( Figure 4C ). Interestingly, loss of Ϫ/Ϫ hearts show disperse fibrotic foci (top images, hematoxylin/eosin-stained; bottom images, Picrosirius red-stained heart sections). C, Thinning of the old Lap2␣ Ϫ/Ϫ myocardium. Arrows mark the transparent fibrotic regions of the heart. LAP2␣ caused a downregulation of connective tissue growth factor, an inducer of fibroblast proliferation and extracellular matrix synthesis, 20 but affected only mildly the expression of its activator, the transforming growth factor ␤ 2 . Altogether, our data demonstrate that loss of LAP2␣ in mice leads to deregulated expression of genes involved in cardiac remodeling and fibrosis.
Lap2␣
؊/؊ Mice Show a Blunted Response to Chronic ISO Infusion GATA4 and MEF2c play important roles during cardiomyocyte hypertrophy. 21, 22 To see whether their deregulation in Lap2␣ Ϫ/Ϫ hearts affects their response to cardiac hypertrophic stimuli, we subjected Lap2␣ Ϫ/Ϫ mice to chronic infusion of the ␤-adrenergic agonist ISO for 7 days. To detect ISO-induced changes in heart function and structure, we performed echocardiography before and after the treatment, as well as gravimetric and histological analyses at the end of the experiment. As shown by the heart weight/body weight indexes, ISO administration caused a similar degree of cardiac hypertrophy in Lap2␣ ϩ/ϩ and Lap2␣ Ϫ/Ϫ mice ( Figure  5A ), indicating that the hypertrophic growth response is not grossly affected by the loss of LAP2␣. Similarly, the extent of subendocardial fibrosis caused by chronic ISO infusion 23 was comparable in Lap2␣ ϩ/ϩ and Lap2␣ Ϫ/Ϫ mice (Online Figure IV) .
In addition to hypertrophy, ISO treatment caused dilation of left heart ventricles, as shown by echocardiography ( Figure   5B and Online Table II) . In WT animals, systolic and diastolic left ventricular diameters and the corresponding ventricular volumes exhibited a significant increase, indicating the progression from cardiac hypertrophy toward heart failure. In contrast, left ventricles of Lap2␣ Ϫ/Ϫ mice were already slightly enlarged at the baseline and showed only milder additional dilation on ISO treatment, reaching end point sizes similar to WT. Heart weight/body weight indexes and echocardiography parameters of sham (PBS)-treated animals were not altered by the procedure (Online Table II ). These data point to a blunted cardiac stress response in LAP2␣-deficient mice.
FS values in treated animals were only slightly affected, showing that chronic ISO infusion did not significantly impair left ventricular systolic function either in Lap2␣ ϩ/ϩ or Lap2␣ Ϫ/Ϫ mice ( Figure 5B and Online Table II ). This is in agreement with previous studies. 23 The preserved basal systolic function in ISO-induced cardiac hypertrophy has been associated with downregu- Ϫ/Ϫ mice exhibit decreased connective tissue growth factor (CTGF) expression and normal transforming growth factor ␤ 2 (TGF␤ 2 ) mRNA content. Quantitative PCR and semiquantitative PCR analyses of heart tissue (nϭ4 to 5 male littermate pairs of each age). One outlier pair was excluded according to Grubb's test. Samples were normalized for endogenous GAPDH levels in semiquantitative PCR and hypoxanthine-guanine phosphoribosyltransferase (HPRT) levels in quantitative PCR and analyzed according to Pfaffl method. 44 Each KO sample was compared to its respective WT littermate sample. Values are mean KO/WT expression ratiosϮSE. *PϽ0.05 (ANOVA). 
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Impaired Heart Function in Lap2␣ ؊/؊ Micelation of ␤-adrenergic receptor (␤-AR)-mediated inotropic responses. 23 An ISO-induced downregulation of ␤-AR has also been shown to cause a blunted reactivity to its subsequent readministration. 23 Therefore, we hypothesized that the reduced responsiveness of Lap2␣ Ϫ/Ϫ myocardium to ISO might also be a consequence of similar desensitization of the ␤-AR signaling pathway. To test this, we analyzed the expression of ␤ 2 -AR in LAP2␣-deficient and WT mice at baseline, as well as after ISO treatment. As expected, Lap2␣ Ϫ/Ϫ hearts showed lower baseline expression levels of ␤ 2 -AR mRNA and protein in young and old mice ( Figure 5C and Online Figure V) . Importantly, the difference in relative ␤ 2 -AR mRNA levels in untreated LAP2␣ KO versus WT hearts increased with age ( Figure 5C ), suggesting that the downregulation of ␤-AR signaling in Lap2␣ Ϫ/Ϫ mice is an aging-dependent phenomenon and may be a consequence of heart function impairment. ISO treatment caused an additional downregulation of ␤ 2 -AR mRNA in Lap2␣ Ϫ/Ϫ hearts, albeit not as extensive as in the WT situation (Ϸ71% in WT versus Ϸ39% in Lap2␣ Ϫ/Ϫ ), resulting in comparable endpoint expression levels in both genotypes ( Figure 5C ).
Development of ␤-AR-mediated hypertrophy is associated with the activation of the fetal cardiac transcriptional program, 23 including the expression of embryonic transcription factors atrial natriuretic factor and GATA4. 24 In accordance with this, atrial natriuretic factor and GATA4 mRNA levels were upregulated in ISO-treated hearts of both Lap2␣ ϩ/ϩ and Lap2␣ Ϫ/Ϫ mice ( Figure 5D ). However, consistent with the reduced ␤-AR levels in old Lap2␣ Ϫ/Ϫ mice, the increase in ISO-induced atrial natriuretic factor expression was significantly lower in LAP2␣-deficient myocardium compared to WT. Relative GATA4 levels were also substantially lower in Lap2␣ Ϫ/Ϫ than in WT hearts after ISO treatment, although the ISO-mediated increase of GATA4 expression was similar in both genotypes. Overall, these results suggest that loss of LAP2␣ affects cardiac-specific transcription and progression of ISO-induced hypertrophy.
Absence of Dystrophin Delays the Onset of Ventricular Dysfunction in Lap2␣
؊/؊
/Mdx Mice
Because baseline systolic dysfunction in Lap2␣ Ϫ/Ϫ mice was not progressive and did not affect their lifespan, we thought that the effect of LAP2␣ loss might be augmented in a cardiomyopathy background. Therefore, we crossed Lap2␣ Ϫ/Ϫ mice with Mdx mutants, 12 which develop skeletal muscle dystrophy and DCM at an advanced age because of the absence of dystrophin. 25, 26 The homozygous Lap2␣ Ϫ/Ϫ /Mdx mutant animals were born according to Mendelian ratios and appeared grossly indistinguishable from their Mdx littermates. Unexpectedly, echocardiography in young Lap2␣ Ϫ/Ϫ /Mdx mice showed normal heart function, with FS values similar to WT and Mdx ( Figure 6 and Online Table III ). This suggests that the absence of dystrophin can presensitize the heart and turn on compensatory pathways leading to a transient rescue of the Lap2␣ Ϫ/Ϫ phenotype. Nevertheless, old compound mutant animals, as well as Mdx mice, developed similar heart function defects as Lap2␣ Ϫ/Ϫ mice ( Figure 6 ; Online Tables  I and III) .
LAP2␣ Is Dispensable in Late-Embryonic and Adult Cardiomyocytes
LAP2␣ is highly expressed in proliferating tissues. 27, 28 Because the majority of adult cardiomyocytes persists in a postmitotic stage, 29 and only low levels of LAP2␣ are present in nuclei throughout adult myocardium (Figure 1 ), 9 we thought that LAP2␣ may exhibit its major activity during early cardiomyocyte proliferation and myocardial growth, when its expression is clearly detectable (Online Figure VI) . To address this question, we generated conditional KO mice by crossing Lap2␣ fl⌬Neo/fl⌬Neo animals with mice expressing Cre recombinase under the control of striated musclespecific muscle creatine kinase (Mck) promoter (Online Figure I) . 30 In this system, the expression of Cre recombinase and the consequent deletion of LAP2␣ are turned on in heart and skeletal muscle during later stages of mouse embryonic development and striated muscle differentiation. Lap2␣ fl⌬Neo/fl⌬Neo /Mck-Cre ϩ mice were born at Mendelian ratios and did not demonstrate any overt phenotype. LAP2␣ mRNA and protein levels were significantly reduced in Lap2␣ fl⌬Neo/fl⌬Neo /Mck-Cre ϩ hearts, indicating an efficient recombination in the myocardium ( Figure 7A ). In contrast, other tissues like spleen, which do not express MCK, 31 had normal levels of LAP2␣ (our unpublished data). Echocardiography in Lap2␣ fl⌬Neo/fl⌬Neo /Mck-Cre ϩ mice showed normal heart function ( Figure 7B and Online Table IV) and histological, as well as morphometric, analyses did not reveal any pathological heart phenotype ( Figure 7C and data not shown) . In accordance, the expression levels of MEF2c and GATA4 mRNA were similar in Lap2␣ fl⌬Neo/fl⌬Neo /Mck-Cre ϩ and Lap2␣ ϩ/ϩ /Mck-Cre ϩ hearts (data not shown). Thus, LAP2␣ expression in late-embryonic and adult cardiomyocytes is dispensable for normal heart function, but may be important during earlier stages of heart development (before embryonic day 13.5 when the Mck promoter becomes active) or in nonstriated muscle cells of the heart.
Discussion
In this study, we describe a new mouse model of cardiomyopathy caused by the absence of LAP2␣, a major binding partner of lamin A/C in the nucleoplasm. 6 Together with previous studies linking lamin A/C and lamin-binding inner nuclear membrane proteins, emerin and nesprin, to congenital heart disorders, 1,3,9,32 our data suggest a major role of A-type lamin complexes in normal heart function.
A mutation in the ␣-specific exon 4 of the human LAP2 gene has previously been linked to familial DCM. 9 Here, we show that the absence of LAP2␣ in mice also leads to a heart disease. Interestingly, only male Lap2␣ Ϫ/Ϫ mice showed a heart defect, whereas female animals exhibited normal cardiac function implicating gender-specific factors in the development of the disease. Similar gender-related phenotype variations were described in other cardiomyopathy mouse models, 33 including mice carrying the H222P-Lmna mutation. 34 Although the exact background of this phenomenon is still unknown, gender-based differences in cardiac dysfunction were linked to the activity of steroid hormones. 35 At present, no data about the risk of heart failure in male versus female carriers of LAP2␣ mutations in humans are available.
In an attempt to disclose the molecular pathways of the disease, we analyzed the expression of factors involved in the development and remodeling of the myocardium. Lap2␣ Ϫ/Ϫ mice showed deregulated expression of major heart transcription factors, MEF2c 14 and GATA4, 17 as well as some of their downstream targets, at different life stages. Both GATA4 and MEF2c play essential roles in embryonic heart development and hypertrophic growth. 14,17,21,22 Because MEF2c is required for normal heart development (see review 14 ), its downregulation in the absence of LAP2␣ might compromise the early stages of cardiac development in Lap2␣ Ϫ/Ϫ mice. The appearance of systolic dysfunction in young Lap2␣ Ϫ/Ϫ mice and the delayed decrease in GATA4 levels only in old mice suggests that this deregulation may be a consequence rather than the cause of the disease. Despite lower GATA4 expression levels, Lap2␣ Ϫ/Ϫ hearts were able to undergo hypertrophic growth. In support of our data, mice with reduced GATA4 levels (G4D mice) show a similar heart function defect at baseline, as well as the ability to grow under hypertrophic conditions. 21 Accordingly, G4D mice develop fibrosis only after pressure overload as a consequence of increased stress-induced cardiomyocyte death. 21 GATA4 and MEF2c synergistically activate the expression of BNP, 18 a cardiac hormone involved in the regulation of blood pressure and fluid-electrolyte balance, which also plays a role in the inhibition of cardiac fibroblast proliferation and extracellular matrix production. 36 Decreased levels of BNP in the absence of LAP2␣ could potentially explain the observed occurrence of cardiac fibrosis in Lap2␣ Ϫ/Ϫ mice. Interestingly, BNP-deficient mice (Nppb Ϫ/Ϫ ), which exhibit normal heart morphology and hypertrophic growth after ventricular pressure overload, show a higher incidence of fibrosis (Ϸ50%) in male versus female mice at the age of 15 weeks. 37 The blunted response of LAP2␣-deficient hearts to chronic ISO infusion points to the existence of compensatory pathways activated in response to changes in cardiac function in Lap2␣ Ϫ/Ϫ mice. The attenuated hypertrophic growth and lack of fibrosis observed in ␤-AR KO mice after pressure overload 38 indicate that the downregulation of ␤-AR signaling found in Lap2␣ Ϫ/Ϫ hearts might be a part of this process. The variability in the extent of fibrosis at baseline, as well as after chronic ISO infusion, might be explained by the observed deregulated expression of pro-connective tissue growth factor and antifibrotic (BNP) factors in Lap2␣ Ϫ/Ϫ mice. The observed downregulation of connective tissue growth factor in old LAP2␣-deficient hearts might be a part of an extensive compensatory mechanism activated in response to loss of LAP2␣ to protect the myocardium from further tissue deterioration and loss of function.
Because LAP2␣ is highly expressed in proliferating tissues and only weakly in postmitotic tissues, 9,27,28 such as heart muscle, 29 we hypothesized that LAP2␣ might be required during cardiac development and/or postnatal myocardial remodeling, mediated by putative cardiac stem cells. 39 Therefore, we generated conditional KO mice that lose LAP2␣ during later stages of embryonic development and adult striated muscle differentiation. 30 Lap2␣ fl⌬Neo/fl⌬Neo /Mck-Cre ϩ mice showed normal heart function and normal levels of GATA4 and MEF2c, supporting the model according to which the defect in complete KO mice might arise during early embryonic development and at early stages of muscle differentiation, before the Mck promoter becomes active, and/or it might be a consequence of LAP2␣ loss from heart stem-and nonstriated muscle cells. We have previously shown that LAP2␣ retains a subfraction of the nuclear lamin A/C pool inside the nucleoplasm in proliferating skin fibroblasts and intestinal cells. In contrast, nucleoplasmic lamin A/C is lost in nondividing differentiated C, Normal heart structure in conditional striated muscle-specific LAP2␣ KO mice.
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؊/؊ Micecells, 8 implicating the nucleoplasmic pool of lamin A/C in regulation of the transition from proliferating to the differentiated state. The localization of lamin A/C has also been shown to change in cardiomyocytes during aging and development, going from being mainly nucleoplasmic to the nuclear periphery. 40 The elongated shape and different orientation of cardiomyocyte nuclei within heart tissue, however, precluded the detection of potential changes in lamin A/C localization in LAP2␣-deficient tissue. In view of the lack of heart defects in muscle-specific conditional LAP2␣ KO mice, there is a possibility that a potential mislocalization of lamin A/C in LAP2␣-deficient cardiomyocyte precursor or nonstriated muscle cells may be the primary cause of the Lap2␣ Ϫ/Ϫ cardiac defect. Alternatively, lack of LAP2␣ may change the function, rather than the localization of lamin A/C, such as binding to epigenetic modifiers and components of different signaling cascades, 7 which in turn may lead to cardiomyopathy. This model is consistent with previous reports that have linked lamin A/C-related cardiomyopathies to changes in signaling pathways, such as transforming growth factor ␤, phosphoinositide 3-kinase and mitogen-activated protein kinase, 41 which influence MEF2c and GATA4 expression during development and hypertrophic growth 42, 43 and are also affected by ␤-AR signaling. 23 In summary, we show that the absence of LAP2␣ causes a baseline ventricular systolic dysfunction in male mice and activates compensatory pathways that prevent further decline of heart function under chronic stress conditions. The origins of these defects, which could lie in impaired proliferation and/or differentiation of early embryonic cardiomyocytes, resident cardiac stem cells, or nonmuscle cardiac tissue, remain to be discovered.
